Findings from Roswell Park-led Children’s Oncology Group Study presented at ASCO Annual Meeting
- New study reports findings of phase II clinical study of combination therapy
- Brentuximab vedotin + gemcitabine given to 42 patients with Hodgkin lymphoma
- Regimen represents a “highly active combination,” researchers report
BUFFALO, N.Y. — New research to be presented at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago shows that a previously untested combination of a monoclonal antibody-drug conjugate with a common chemotherapy agent has a high complete-response rate in children and young adults with relapsed or refractory Hodgkin lymphoma. This cooperative-group clinical trial, Children’s Oncology Group study AHOD1221 (NCT01780662), was led by Kara Kelly, MD, Waldemar J. Kaminski Endowed Chair of Pediatrics at Roswell Park Comprehensive Cancer Center.
The research team evaluated the combination of the biologic therapy brentuximab vedotin (Adcetris), a monoclonal antibody-drug conjugate, with the chemotherapy drug gemcitabine (Gemzar) in 42 pediatric and young-adult patients with Hodgkin lymphoma, the most common cancer in young people ages 15 to 29.
The researchers report that these two therapies together represent a highly active combination for refractory or relapsed Hodgkin lymphoma, with a complete response rate exceeding that seen with standard therapy or following administration of either brentuximab vedotin or gemcitabine alone. Among the evaluable patients in the newly reported phase II study, 23 (58%) achieved complete response to the combination within four cycles, and 6 (15%) had a partial response.
“We found very high response rates to this treatment combination, which has the added benefit of having a much reduced risk of long-term organ damage compared to the highly toxic chemotherapy agents typically used for patients with relapsed Hodgkin lymphoma,” says Dr. Kelly, who is Program Director of the Pediatric Hematology/Oncology Service Line at the Women & Children’s Hospital of Buffalo and holds an additional faculty appointment with the University at Buffalo. “We’re encouraged at the prospect that these findings, if confirmed in a phase III study, might represent a new standard of care for one of our most common pediatric and young-adult cancers.”
Researchers from several institutions collaborated on this research: Children’s Hospital at Montefiore, Rhode Island Hospital, St. Jude Children’s Research Hospital, the Cancer Institute of New Jersey, Baylor College of Medicine, Children’s Oncology Group, Children’s Cancer Center at Baylor College of Medicine and the University of Minnesota.
The poster, “Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): A Children’s Oncology Group (COG) report,” is ASCO 2017 abstract 7527 and will be presented Monday, June 5, from 8 a.m. to 11:30 a.m. CDT in McCormick Place, Hall A, as part of the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia session.
The mission of Roswell Park Comprehensive Cancer Center is to understand, prevent and cure cancer. Founded in 1898, Roswell Park is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-Roswell Park (1-866-559-4838) or email AskRoswell@Roswellpark.org. Follow Roswell Park on Facebook and Twitter.
Annie Deck-Miller, Senior Media Relations Manager